Merck Says R&D Efficiency Is Above Average, Rx Prices Not Tied To Research
Executive Summary
The increasing cost of drug development will force companies to compete based on the efficiency of their R&D programs, Merck CEO Raymond Gilmartin suggested during a Nov. 30 Tufts Center for the Study of Drug Development briefing in Philadelphia
You may also be interested in...
Rx Prices Reflect “Anticipated Income,” Not R&D Costs, Pfizer CEO Says
Pharmaceutical pricing decisions are based on "anticipated income" rather than achieving a return on R&D costs, Pfizer CEO Hank McKinnell writes in his recently published book A Call To Action: Taking Back Healthcare for Future Generations
Rx Prices Reflect “Anticipated Income,” Not R&D Costs, Pfizer CEO Says
Pharmaceutical pricing decisions are based on "anticipated income" rather than achieving a return on R&D costs, Pfizer CEO Hank McKinnell writes in his recently published book A Call To Action: Taking Back Healthcare for Future Generations
Big Pharma Likes Big Trials, Biotech CEO Says; Tufts Defends R&D Estimate
Large pharmaceutical companies are comfortable with high R&D costs because they create a barrier to entry in the industry, Cancer Therapeutics, Inc. CEO Robert Oldham, MD, maintained during a Capitol Hill briefing sponsored by the Manhattan Institute June 3